Sam Brusco, Associate Editor11.15.22
Kindeva Drug Delivery (formerly 3M Drug Delivery Systems) will combine with Meridian Medical Technologies, creating a new global drug-device combination product contract development and manufacturing organization. The companies will continue to operate independently until the deal has closed.
The combined company will have expertise and tech spanning the parenteral, inhalation, transdermal, and intradermal administration routes.
“We are incredibly excited about the opportunities that will result from the combination of two companies with deep roots in complex drug delivery,” Milton Boyer, CEO of Meridian who will be CEO of the newly combined company, told the press. “The integrated, complementary offerings of Kindeva and Meridian create a CDMO with a broad portfolio of capabilities and proprietary technology platforms across multiple drug delivery formats, enabling us to serve customers and communities across multiple large and growing end markets.”
Kindeva was acquired by healthcare investment firm Altaris from 3M in 2020. Meridian was acquired by Altaris from Pfizer in December 2021. The company focuses on manufacturing rescue autoinjectors, having pioneered the tech in the 1950s.
The combined company will have expertise and tech spanning the parenteral, inhalation, transdermal, and intradermal administration routes.
“We are incredibly excited about the opportunities that will result from the combination of two companies with deep roots in complex drug delivery,” Milton Boyer, CEO of Meridian who will be CEO of the newly combined company, told the press. “The integrated, complementary offerings of Kindeva and Meridian create a CDMO with a broad portfolio of capabilities and proprietary technology platforms across multiple drug delivery formats, enabling us to serve customers and communities across multiple large and growing end markets.”
Kindeva was acquired by healthcare investment firm Altaris from 3M in 2020. Meridian was acquired by Altaris from Pfizer in December 2021. The company focuses on manufacturing rescue autoinjectors, having pioneered the tech in the 1950s.